A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial product is MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, and 20 mg tablets, which the FDA approved in December 2025. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. The approval of MYQORZO included a risk evaluation and mitigation strategy (REMS) program to ensure the benefits of the drug outweigh the risk of heart failure due to systolic dysfunction.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -785M | -785M | -590M | -526M | -389M | -215M |
| EPS | $-6.54 | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Free Cash Flow | -535M | -535M | -400M | -416M | -311M | -191M |
| ROIC | -34.0% | -43.0% | -38.3% | -60.2% | -25.2% | -95.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.63 | -1.75 | -0.54 | -1.90 | 0.72 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -612M | -612M | -536M | -496M | -324M | -186M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | 197.5% | 226.0% | 213.0% | - | -120.5% |
| Shares Outstanding | 120M | 120M | 112M | 97M | 90M | 77M |
CYTOKINETICS INC passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +22.8%.
CYTOKINETICS INC (CYTK) has a 5-year average return on invested capital (ROIC) of -52.4%. This is below average and may indicate limited pricing power.
CYTOKINETICS INC (CYTK) has a market capitalization of $8.0B. It is classified as a mid-cap stock.
CYTOKINETICS INC (CYTK) does not currently pay a regular dividend.
CYTOKINETICS INC (CYTK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CYTOKINETICS INC (CYTK) generated $-535 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CYTOKINETICS INC (CYTK) reported earnings per share (EPS) of $-6.54 in its most recent fiscal year.
CYTOKINETICS INC (CYTK) has a return on equity (ROE) of 197.5%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 16 years of financial data for CYTOKINETICS INC (CYTK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CYTOKINETICS INC (CYTK) has a book value per share of $-5.50, based on its most recent annual SEC filing.